Calvo Felipe A, Domper Marta, Matute Raúl, Martínez-Lázaro Raúl, Arranz José A, Desco Manuel, Alvarez Emilio, Carreras José Luis
Department of Oncology, Hospital General Universitario Gregorio Marañón, C/Dr. Esquerdo 46, Madrid 28007, Spain.
Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):528-35. doi: 10.1016/j.ijrobp.2003.09.058.
To assess the information supplied by FDG-PET in patients with locally advanced rectal cancer both in the initial staging and in the evaluation of tumor changes induced by preoperative chemoradiation (restaging).
Twenty-five consecutive patients with rectal cancer were included, with tumor stages (c)T(2-4)N(x)M(0), during the period 1997-1999. We prospectively performed two FDG-PET scans in all patients to assess disease stage (1) at initial diagnosis and (2) presurgically, 4 to 5 weeks after protracted chemoradiation. Protracted chemoradiation was carried out during 5-6 weeks with 45-50 Gy, plus concurrent oral tegafur 1200 mg/day or 5-fluorouracil 500-1000 mg/m(2) administered as a 24-h continuous i.v. infusion on Days 1-4 and 21-25 of the radiotherapy treatment. Tumors were staged with CT in 95% of patients, whereas endorectal ultrasound was used in 90% of patients. Maximum standardized uptake value (SUVmax) was used as the quantitative parameter to estimate the tumor:tissue metabolic ratio.
Preoperative chemoradiation significantly decreased the SUVMAX: 5.9 (mean SUVmax at initial staging) vs. 2.4 (mean SUVmax after chemoradiation) with p < 0.001. Unknown liver metastases were detected by FDG-PET in 2 patients, in 1 of them with the initial staging FDG-PET scan, and with the restaging FDG-PET scan in the other. After an average follow-up of 39 months, the value of SUVmax > or =6 allowed us to discriminate for survival at 3 years: 92% vs. 60% (p = 0.04). T downstaging (total 62%) was significantly correlated with SUVmax changes: 1.9 vs. 3.3 (p = 0.03). The degree of rectal cancer response to chemoradiation, established as mic vs. mac categories, was not associated with SUVmax differences (mean values of 2.0 vs. 2.7).
Preliminary results observed suggest the potential utility of FDG-PET as a complementary diagnostic procedure in the initial clinical evaluation (8% of unsuspected liver metastases) as well as in the assessment of chemoradiation response (any T downstaged event) of locally advanced rectal cancer. Initial SUVmax might be of prognostic value related to long-term patient outcome.
评估氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)在局部晚期直肠癌患者初始分期以及术前放化疗诱导的肿瘤变化评估(再分期)中所提供的信息。
纳入1997年至1999年期间连续的25例直肠癌患者,肿瘤分期为(c)T(2 - 4)N(x)M(0)。我们前瞻性地对所有患者进行了两次FDG-PET扫描,以评估疾病分期:(1)初始诊断时;(2)术前,在长时间放化疗4至5周后。长时间放化疗在5 - 6周内进行,剂量为45 - 50 Gy,同时口服替加氟1200 mg/天或5-氟尿嘧啶500 - 1000 mg/m²,在放疗治疗的第1 - 4天和第21 - 25天进行24小时持续静脉输注。95%的患者通过CT对肿瘤进行分期,90%的患者使用直肠内超声。最大标准化摄取值(SUVmax)用作估计肿瘤:组织代谢率的定量参数。
术前放化疗显著降低了SUVmax:初始分期时平均SUVmax为5.9,放化疗后为2.4,p < 0.001。FDG-PET在2例患者中检测到未知的肝转移,其中1例在初始分期FDG-PET扫描时发现,另1例在再分期FDG-PET扫描时发现。平均随访39个月后,SUVmax≥6的值使我们能够区分3年生存率:92%对60%(p = 0.04)。T分期降低(总计62%)与SUVmax变化显著相关:1.9对3.3(p = 0.03)。直肠癌对放化疗的反应程度,分为微观与宏观类别,与SUVmax差异无关(平均值分别为2.0和2.7)。
观察到的初步结果表明,FDG-PET在初始临床评估(8%的未怀疑肝转移)以及局部晚期直肠癌放化疗反应评估(任何T分期降低事件)中作为一种补充诊断方法具有潜在效用。初始SUVmax可能与患者长期预后具有预后价值。